title: The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients.
abstract: This study was conducted to compare the efficacy and safety of bupropion sustained-release (SR) formulation orally administered at daily doses of 150 mg/day (once daily) and 300 mg/day (150 mg twice daily) for 8 weeks versus placebo in Asian patients with major depressive disorder. The mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at week 8 was compared between each of the bupropion SR dose groups and the placebo group using an analysis of covariance with the multiplicity adjustment by Dunnett's step-down procedure. A total of 569 subjects met all of the inclusion criteria and proceeded to the treatment phase. The subjects proceeding to the treatment phase included 454 Japanese patients and 115 Korean patients. There was no statistically significant difference between each of the bupropion SR dose groups and the placebo group in the primary efficacy endpoint of change from baseline in MADRS total score at week 8. Similar results were generally obtained for all of the secondary efficacy endpoints. The secondary analysis and the other subgroup analysis did not show a statistically significant difference in efficacy. There was no substantial difference in the type, severity, and incidence of adverse events (AEs) between the bupropion SR dose groups and the placebo group, which indicates a favorable safety profile for bupropion SR. There were no significant findings in subjects treated with bupropion SR in regard to sexual dysfunction, weight change, and withdrawal syndrome, which are frequently recognized as clinical concerns associated with selective serotonin reuptake inhibitors, widely used for the treatment of depression.
authors.affiliation: Iris Medical Clinic, Kanazawa University, Ishikawa, Japan.
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Koshino
authors.forename: Won-Myong
authors.initials: WM
authors.lastname: Bahk
authors.forename: Hideaki
authors.initials: H
authors.lastname: Sakai
authors.forename: Takayuki
authors.initials: T
authors.lastname: Kobayashi
keywords: Japan; Korea; bupropion SR; major depressive disorder; placebo
references.citation: J Postgrad Med. 2001 Jan-Mar;47(1):45-50
references.pmid: 11590294
references.citation: J Clin Psychiatry. 2005 Aug;66(8):974-81
references.pmid: 16086611
references.citation: J Clin Psychiatry. 2006 Jun;67(6):865-73
references.pmid: 16848645
references.citation: Psychiatry Clin Neurosci. 2013 May;67(4):253-8
references.pmid: 23683156
references.citation: Clin Ther. 2001 Jul;23(7):1040-58
references.pmid: 11519769
references.citation: Br J Psychiatry. 1979 Apr;134:382-9
references.pmid: 444788
references.citation: Expert Rev Neurother. 2007 Oct;7(10):1251-63
references.pmid: 17939764
references.citation: J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
references.pmid: 14399272
references.citation: Am J Psychiatry. 2002 Feb;159(2):191-200
references.pmid: 11823258
references.citation: Neuropsychopharmacology. 2005 Mar;30(3):445-60
references.pmid: 15647752
references.citation: Drug Saf. 2001;24(3):183-97
references.pmid: 11347722
references.citation: Prim Care Companion J Clin Psychiatry. 2005;7(3):106-13
references.pmid: 16027765
references.citation: J Clin Psychiatry. 2002 Apr;63(4):357-66
references.pmid: 12000211
references.citation: Psychol Med. 1996 May;26(3):477-86
references.pmid: 8733206
references.citation: J Neurolinguistics. 2007 Jan;20(1):50-64
references.pmid: 21253440
references.citation: J Clin Psychopharmacol. 2007 Apr;27(2):121-5
references.pmid: 17414233
references.citation: Lancet. 2009 Feb 28;373(9665):746-58
references.pmid: 19185342
references.citation: J Clin Psychiatry. 2010 Oct;71(10):1259-72
references.pmid: 21062615